Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study

Abstract Background Immune checkpoint inhibitor doublet (ICI-ICI) and ICI plus tyrosine kinase inhibitor (ICI-TKI) regimens are the cornerstone of treatment for metastatic renal cell carcinoma (mRCC), although no head-to-head comparisons are currently available. This study aimed to compare the real-...

Descripció completa

Dades bibliogràfiques

Autors principals:	Michele Maffezzoli, Alessio Signori, Alessandro Acunzo, Sebastiano Buti, Michela Bosoni, Elena Verzoni, Andrea Di Marco, Cristian Lolli, Marilena Di Napoli, Martina Fanelli, Alberto Dalla Volta, Cristina Masini, Giandomenico Roviello, Roberto Iacovelli, Alessia Mennitto, Roberto Filippi, Mariella Sorarù, Luigi Formisano, Annalisa Guida, Emanuela Fantinel, Carlo Messina, Lucia Bonomi, Sarah Scagliarini, Cecilia Nasso, Silvia Chiellino, Brigida Anna Maiorano, Filippo Deppieri, Alessia Cavo, Vincenza Conteduca, Silvia Zai, Paolo Andrea Zucali, Marcello Tucci, Francesca Vignani, Francesca La Russa, Laura Lombardo, Claudia Caserta, Federico Paolieri, Francesca Bertolotti, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Davide Bimbatti, Sara Elena Rebuzzi
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2026-02-01
Col·lecció:	Cancer Immunology, Immunotherapy
Matèries:	Metastatic renal cell carcinoma Real-world ICI TKI Intermediate Poor
Accés en línia:	https://doi.org/10.1007/s00262-026-04318-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!